HARPOON THERAPEUTICS INC (HARP) Stock Price, Forecast & Analysis
USA - NASDAQ:HARP - US41358P2056 - Common Stock
HARP Key Statistics, Chart & Performance
The current stock price of HARP is 23.01 USD. In the past month the price increased by 3%. In the past year, price increased by 248.64%.
HARP Latest News, Press Relases and Analysis
HARP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| ARGX | ARGENX SE - ADR | 63.46 | 52.40B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.37 | 36.51B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B |
Related stock screener links
About HARP
Company Profile
Harpoon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2019-02-08. Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The firm is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Company Info
HARPOON THERAPEUTICS INC
611 Gateway Boulevard, Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Gerald McMahon
Employees: 53
Phone: 16504437400
HARPOON THERAPEUTICS INC / HARP FAQ
What does HARP do?
Harpoon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2019-02-08. Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The firm is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Can you provide the latest stock price for HARPOON THERAPEUTICS INC?
The current stock price of HARP is 23.01 USD. The price increased by 0.09% in the last trading session.
What is the dividend status of HARPOON THERAPEUTICS INC?
HARP does not pay a dividend.
How is the ChartMill rating for HARPOON THERAPEUTICS INC?
HARP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about HARPOON THERAPEUTICS INC (HARP) stock?
15 analysts have analysed HARP and the average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01.
When does HARPOON THERAPEUTICS INC (HARP) report earnings?
HARPOON THERAPEUTICS INC (HARP) will report earnings on 2024-03-25, after the market close.
HARP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HARP. When comparing the yearly performance of all stocks, HARP is one of the better performing stocks in the market, outperforming 99.07% of all stocks.
HARP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HARP. HARP has a bad profitability rating. Also its financial health evaluation is rather negative.
HARP Financial Highlights
Over the last trailing twelve months HARP reported a non-GAAP Earnings per Share(EPS) of -8.76. The EPS increased by 44.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.08% | ||
| ROE | -677.78% | ||
| Debt/Equity | 1.96 |
HARP Forecast & Estimates
15 analysts have analysed HARP and the average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01.
For the next year, analysts expect an EPS growth of 90.06% and a revenue growth 8.24% for HARP